The role of Matrix Metalloproteinase-13 (MMP-13) in the reversibility of liver fibrosis.

Lead Research Organisation: University Hospital Southampton NHS Foundation Trust
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications

10 25 50
 
Description Galecto Scientific Advisory Board
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Confidence in Concept
Amount £67,337 (GBP)
Funding ID MRC/CIC6/54 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 06/2018 
End 05/2019
 
Description Diabetes UK
Amount £350,000 (GBP)
Organisation Diabetes UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2011 
End 06/2014
 
Description Diabetes UK
Amount £263,902 (GBP)
Funding ID 17/0005697 
Organisation Diabetes UK 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2017 
End 11/2020
 
Description Intercept Pharmaceuticals Sponsored Research Agreement
Amount £386,000 (GBP)
Organisation Intercept Pharmaceuticals 
Sector Private
Country United States
Start 03/2017 
End 05/2018
 
Description MRC BMC MAC
Amount £3,600,000 (GBP)
Funding ID MR/M007588/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 02/2015 
End 02/2020
 
Description Nottingham Molecular Pathology Node Flexifund award
Amount £29,000 (GBP)
Organisation University of Nottingham 
Sector Academic/University
Country United Kingdom
Start 07/2017 
 
Description Wellcome Trust Institutional Strategic Support Fund
Amount £25,886 (GBP)
Organisation Wellcome Trust 
Department Wellcome Trust Institutional Strategic Support Fund
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
End 04/2016
 
Description Wellcome Trust Institutional Translational Partnership Award
Amount £13,845 (GBP)
Funding ID WT iTPA PIII-003 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2018 
 
Description Wellcome Trust/Scottish Translational Medicine and Therapeutics Initiative
Amount £244,706 (GBP)
Funding ID WT 085664 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2011 
End 04/2014
 
Title Preclinical LiverMultiscan MRI 
Description Non-invasive assessment of liver disease in rodent models using multiparameter MRI - pilot study undertaken. Addresses the 3Rs as it may change the way we model/monitor liver disease in preclinical models - serial measurements as opposed to multiple timepoint culls. Same technology as clinical LiverMultiscan MRI but we miniaturised/developed the platform for our small animal MRI scanner. 
Type Of Material Data analysis technique 
Provided To Others? No  
Impact Presented data (poster) at local 3Rs conference. 
URL http://perspectum-diagnostics.com/
 
Description GSK Discovery Partnerships with Academia (DPAc) 
Organisation GlaxoSmithKline (GSK)
Department Discovery Partnerships with Academia
Country Global 
Sector Private 
PI Contribution Background data. Disease models. Clinical need/applications.
Collaborator Contribution Drug discovery. Assay development. Medicinal chemistry. Funding.
Impact It is too early for tangible outputs. Manuscript in preparation.
Start Year 2014
 
Description Intercept Pharmaceuticals collaboration 
Organisation Intercept Pharmaceuticals
Country United States 
Sector Private 
PI Contribution Study design, execution of the study, data analysis.
Collaborator Contribution Proprietary IP. Methodology input. Materials transfer.
Impact Too early to report.
Start Year 2016
 
Description Liver fibrosis - image analysis and tissue biomarkers 
Organisation University of Nottingham
Department School of Life Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Liver fibrosis and elastin - biological understanding, human tissue samples, immunohistochemistry, automated analysis.
Collaborator Contribution Clinical disease cohort. Histology and image analysis platforms.
Impact Abstracts at BASL and AASLD conferences 2013. Joint Edinburgh/Nottingham manuscript in preparation. Application for funding from Nottingham Molecular Pathology Node.
Start Year 2012
 
Description MRC mouse network 
Organisation Medical Research Council (MRC)
Country United Kingdom 
Sector Academic/University 
PI Contribution I joined a UK multicentre consortium (Tissue Remodelling and Fibrosis Consortium) and our bid for MRC mouse network funding was successful.
Impact Not yet, but one of our genes of interest is a year 1 priority KO mouse target.
Start Year 2011
 
Description Macrophage Therapy for Liver Cirrhosis 
Organisation University of Edinburgh
Department MRC Centre for Regenerative Medicine
Country United Kingdom 
Sector Public 
PI Contribution Co-investigator on this MRC funded phase 1/2 clinical trial.
Collaborator Contribution Clinical imaging, study endpoints, study design.
Impact Phase 1 (dose escalation) has commenced.
Start Year 2015
 
Description SteatoSITE NAFLD Data Commons 
Organisation Eagle Genomics Ltd
PI Contribution 'SteatoSITE: an integrated gene-to-patient data commons for NAFLD research' is a retrospective study funded by Innovate UK (TSB Ref: TS/R017581/1), collecting archived liver samples from the NHS Research Scotland Biorepositories (needle biopsies, resections and explants) to generate de novo transcriptomic and digital pathology outputs from 1000 cases and 100 healthy controls, with complementary clinical information sourced via the NHS Safe Havens; forming the basis for a comprehensive knowledge system that centralises, standardises and makes data accessible for academic research, clinical/quality improvement, and industry research and development (27 companies engaged to date). I am the Chief Investigator/Clinical Lead for this consortium project. University of Edinburgh is also leading the Pathology work package and Edinburgh Genomics are performing the liver tissue RNA sequencing.
Collaborator Contribution Eagle Genomics - Industry partner SMS-IC - project management, building the sequencing libraries, IT support, business development University of Glasgow, University of Dundee, University of Aberdeen - tissue sourcing via biorepositories, scientific advisory board members
Impact We have just completed an initial n=60 case pilot study to test feasibility, establish SOPs and validate/QC the RNA sequencing approach. Data will be presented at the National Hepatology Research Day, Dundee, April 2019.
Start Year 2018
 
Description SteatoSITE NAFLD Data Commons 
Organisation Innovate UK
Country United Kingdom 
Sector Public 
PI Contribution 'SteatoSITE: an integrated gene-to-patient data commons for NAFLD research' is a retrospective study funded by Innovate UK (TSB Ref: TS/R017581/1), collecting archived liver samples from the NHS Research Scotland Biorepositories (needle biopsies, resections and explants) to generate de novo transcriptomic and digital pathology outputs from 1000 cases and 100 healthy controls, with complementary clinical information sourced via the NHS Safe Havens; forming the basis for a comprehensive knowledge system that centralises, standardises and makes data accessible for academic research, clinical/quality improvement, and industry research and development (27 companies engaged to date). I am the Chief Investigator/Clinical Lead for this consortium project. University of Edinburgh is also leading the Pathology work package and Edinburgh Genomics are performing the liver tissue RNA sequencing.
Collaborator Contribution Eagle Genomics - Industry partner SMS-IC - project management, building the sequencing libraries, IT support, business development University of Glasgow, University of Dundee, University of Aberdeen - tissue sourcing via biorepositories, scientific advisory board members
Impact We have just completed an initial n=60 case pilot study to test feasibility, establish SOPs and validate/QC the RNA sequencing approach. Data will be presented at the National Hepatology Research Day, Dundee, April 2019.
Start Year 2018
 
Description SteatoSITE NAFLD Data Commons 
Organisation Stratified Medicine Scotland Innovation Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution 'SteatoSITE: an integrated gene-to-patient data commons for NAFLD research' is a retrospective study funded by Innovate UK (TSB Ref: TS/R017581/1), collecting archived liver samples from the NHS Research Scotland Biorepositories (needle biopsies, resections and explants) to generate de novo transcriptomic and digital pathology outputs from 1000 cases and 100 healthy controls, with complementary clinical information sourced via the NHS Safe Havens; forming the basis for a comprehensive knowledge system that centralises, standardises and makes data accessible for academic research, clinical/quality improvement, and industry research and development (27 companies engaged to date). I am the Chief Investigator/Clinical Lead for this consortium project. University of Edinburgh is also leading the Pathology work package and Edinburgh Genomics are performing the liver tissue RNA sequencing.
Collaborator Contribution Eagle Genomics - Industry partner SMS-IC - project management, building the sequencing libraries, IT support, business development University of Glasgow, University of Dundee, University of Aberdeen - tissue sourcing via biorepositories, scientific advisory board members
Impact We have just completed an initial n=60 case pilot study to test feasibility, establish SOPs and validate/QC the RNA sequencing approach. Data will be presented at the National Hepatology Research Day, Dundee, April 2019.
Start Year 2018
 
Description SteatoSITE NAFLD Data Commons 
Organisation University of Aberdeen
Country United Kingdom 
Sector Academic/University 
PI Contribution 'SteatoSITE: an integrated gene-to-patient data commons for NAFLD research' is a retrospective study funded by Innovate UK (TSB Ref: TS/R017581/1), collecting archived liver samples from the NHS Research Scotland Biorepositories (needle biopsies, resections and explants) to generate de novo transcriptomic and digital pathology outputs from 1000 cases and 100 healthy controls, with complementary clinical information sourced via the NHS Safe Havens; forming the basis for a comprehensive knowledge system that centralises, standardises and makes data accessible for academic research, clinical/quality improvement, and industry research and development (27 companies engaged to date). I am the Chief Investigator/Clinical Lead for this consortium project. University of Edinburgh is also leading the Pathology work package and Edinburgh Genomics are performing the liver tissue RNA sequencing.
Collaborator Contribution Eagle Genomics - Industry partner SMS-IC - project management, building the sequencing libraries, IT support, business development University of Glasgow, University of Dundee, University of Aberdeen - tissue sourcing via biorepositories, scientific advisory board members
Impact We have just completed an initial n=60 case pilot study to test feasibility, establish SOPs and validate/QC the RNA sequencing approach. Data will be presented at the National Hepatology Research Day, Dundee, April 2019.
Start Year 2018
 
Description SteatoSITE NAFLD Data Commons 
Organisation University of Dundee
Country United Kingdom 
Sector Academic/University 
PI Contribution 'SteatoSITE: an integrated gene-to-patient data commons for NAFLD research' is a retrospective study funded by Innovate UK (TSB Ref: TS/R017581/1), collecting archived liver samples from the NHS Research Scotland Biorepositories (needle biopsies, resections and explants) to generate de novo transcriptomic and digital pathology outputs from 1000 cases and 100 healthy controls, with complementary clinical information sourced via the NHS Safe Havens; forming the basis for a comprehensive knowledge system that centralises, standardises and makes data accessible for academic research, clinical/quality improvement, and industry research and development (27 companies engaged to date). I am the Chief Investigator/Clinical Lead for this consortium project. University of Edinburgh is also leading the Pathology work package and Edinburgh Genomics are performing the liver tissue RNA sequencing.
Collaborator Contribution Eagle Genomics - Industry partner SMS-IC - project management, building the sequencing libraries, IT support, business development University of Glasgow, University of Dundee, University of Aberdeen - tissue sourcing via biorepositories, scientific advisory board members
Impact We have just completed an initial n=60 case pilot study to test feasibility, establish SOPs and validate/QC the RNA sequencing approach. Data will be presented at the National Hepatology Research Day, Dundee, April 2019.
Start Year 2018
 
Description SteatoSITE NAFLD Data Commons 
Organisation University of Edinburgh
Department Edinburgh Genomics
Country United Kingdom 
Sector Private 
PI Contribution 'SteatoSITE: an integrated gene-to-patient data commons for NAFLD research' is a retrospective study funded by Innovate UK (TSB Ref: TS/R017581/1), collecting archived liver samples from the NHS Research Scotland Biorepositories (needle biopsies, resections and explants) to generate de novo transcriptomic and digital pathology outputs from 1000 cases and 100 healthy controls, with complementary clinical information sourced via the NHS Safe Havens; forming the basis for a comprehensive knowledge system that centralises, standardises and makes data accessible for academic research, clinical/quality improvement, and industry research and development (27 companies engaged to date). I am the Chief Investigator/Clinical Lead for this consortium project. University of Edinburgh is also leading the Pathology work package and Edinburgh Genomics are performing the liver tissue RNA sequencing.
Collaborator Contribution Eagle Genomics - Industry partner SMS-IC - project management, building the sequencing libraries, IT support, business development University of Glasgow, University of Dundee, University of Aberdeen - tissue sourcing via biorepositories, scientific advisory board members
Impact We have just completed an initial n=60 case pilot study to test feasibility, establish SOPs and validate/QC the RNA sequencing approach. Data will be presented at the National Hepatology Research Day, Dundee, April 2019.
Start Year 2018
 
Description SteatoSITE NAFLD Data Commons 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution 'SteatoSITE: an integrated gene-to-patient data commons for NAFLD research' is a retrospective study funded by Innovate UK (TSB Ref: TS/R017581/1), collecting archived liver samples from the NHS Research Scotland Biorepositories (needle biopsies, resections and explants) to generate de novo transcriptomic and digital pathology outputs from 1000 cases and 100 healthy controls, with complementary clinical information sourced via the NHS Safe Havens; forming the basis for a comprehensive knowledge system that centralises, standardises and makes data accessible for academic research, clinical/quality improvement, and industry research and development (27 companies engaged to date). I am the Chief Investigator/Clinical Lead for this consortium project. University of Edinburgh is also leading the Pathology work package and Edinburgh Genomics are performing the liver tissue RNA sequencing.
Collaborator Contribution Eagle Genomics - Industry partner SMS-IC - project management, building the sequencing libraries, IT support, business development University of Glasgow, University of Dundee, University of Aberdeen - tissue sourcing via biorepositories, scientific advisory board members
Impact We have just completed an initial n=60 case pilot study to test feasibility, establish SOPs and validate/QC the RNA sequencing approach. Data will be presented at the National Hepatology Research Day, Dundee, April 2019.
Start Year 2018
 
Description Technology Strategy Board consortium - Advancing in-vivo imaging for stratified medicine 
Organisation Perspectum Diagnosis
Country United Kingdom 
Sector Private 
PI Contribution Patient cohorts. Medical physics and infrastructure. Liver fibrosis understanding.
Collaborator Contribution Partial funding from Perspectum (also MRI acquisition platform and analysis). Pilot study data from Oxford. Trial design.
Impact Multiple abstracts at conferences based upon our Innovate-UK funded study. Two manuscripts published. Another Innovate-UK grant (Biomedical Catalyst) recently awarded (1.1M GBP) to Perspectum Diagnostics, University of Edinburgh and Basingstoke Hospital to use the LiverMultiscan technology to assess liver health in surgical planning. LiverMultiscan is now FDA 510(k) cleared in the U.S. and CE marked by notified body BSI 0086 in Europe to aid clinicians in the diagnosis of liver disorders and abnormalities. The company Perspectum has expanded massively from initial spin-out from University of Oxford - now has offices in Oxford, San Francisco and Singapore and employs many staff. The technology is being appraised by NICE and may enter NHS clinical pathways in the near future. LiverMultiscan is already being used in clinical trials in NASH as a surrogate endpoint.
Start Year 2013
 
Description Technology Strategy Board consortium - Advancing in-vivo imaging for stratified medicine 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Patient cohorts. Medical physics and infrastructure. Liver fibrosis understanding.
Collaborator Contribution Partial funding from Perspectum (also MRI acquisition platform and analysis). Pilot study data from Oxford. Trial design.
Impact Multiple abstracts at conferences based upon our Innovate-UK funded study. Two manuscripts published. Another Innovate-UK grant (Biomedical Catalyst) recently awarded (1.1M GBP) to Perspectum Diagnostics, University of Edinburgh and Basingstoke Hospital to use the LiverMultiscan technology to assess liver health in surgical planning. LiverMultiscan is now FDA 510(k) cleared in the U.S. and CE marked by notified body BSI 0086 in Europe to aid clinicians in the diagnosis of liver disorders and abnormalities. The company Perspectum has expanded massively from initial spin-out from University of Oxford - now has offices in Oxford, San Francisco and Singapore and employs many staff. The technology is being appraised by NICE and may enter NHS clinical pathways in the near future. LiverMultiscan is already being used in clinical trials in NASH as a surrogate endpoint.
Start Year 2013
 
Description Technology Strategy Board consortium - Advancing in-vivo imaging for stratified medicine 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Patient cohorts. Medical physics and infrastructure. Liver fibrosis understanding.
Collaborator Contribution Partial funding from Perspectum (also MRI acquisition platform and analysis). Pilot study data from Oxford. Trial design.
Impact Multiple abstracts at conferences based upon our Innovate-UK funded study. Two manuscripts published. Another Innovate-UK grant (Biomedical Catalyst) recently awarded (1.1M GBP) to Perspectum Diagnostics, University of Edinburgh and Basingstoke Hospital to use the LiverMultiscan technology to assess liver health in surgical planning. LiverMultiscan is now FDA 510(k) cleared in the U.S. and CE marked by notified body BSI 0086 in Europe to aid clinicians in the diagnosis of liver disorders and abnormalities. The company Perspectum has expanded massively from initial spin-out from University of Oxford - now has offices in Oxford, San Francisco and Singapore and employs many staff. The technology is being appraised by NICE and may enter NHS clinical pathways in the near future. LiverMultiscan is already being used in clinical trials in NASH as a surrogate endpoint.
Start Year 2013
 
Title Autologous macrophage infusion 
Description MRC have just awarded £3.6M via BMC MAC for study 'Autologous macrophage therapy for liver cirrhosis' (Professor SJ Forbes CI,; Dr JA Fallowfield co-I). Start date was Feb 2015 for 5 years. 
Type Therapeutic Intervention - Cellular and gene therapies
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2015
Development Status Under active development/distribution
Impact Process optimisation. GMP grade production of cell therapy product and in vitro characterisation etc published. 
 
Title Liver Multiscan 
Description Liver Multiscan is a new MRI acquisition to quantify liver fibrosis, iron and fat patented by Perspectum diagnostics. We are conducting a 2-centre clinical validation trial in Edinburgh and Birmingham funded by TSB. A pilot trial (RIAL study) has already been undertaken: NCT01543646. 
Type Diagnostic Tool - Imaging
Current Stage Of Development Late clinical evaluation
Year Development Stage Completed 2014
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Too early to judge but may replace need for liver biopsy in many situations and accelerate drug development in chronic fibrotic liver disease. 
 
Description School visit (Hampshire) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Schools
Results and Impact School visit - talk about 'liver disease' to ~150 pupils and Q+A classroom visit.

None specifically.
Year(s) Of Engagement Activity 2007
 
Description University of Edinburgh Careers Fair 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Regional
Primary Audience Undergraduate students
Results and Impact 100-200 undergraduate students attended my stand promoting academic medicine.

Some follow-up discussions with interested students.
Year(s) Of Engagement Activity 2011,2012